A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.
Benjamin Musher(Baylor College of Medicine), Angelica Sara Ingrid Loskog(Uppsala University), Ann M. Leen(Texas Children's Hospital), Brandon G. Smaglo(The University of Texas MD Anderson Cancer Center), Gustav Ullenhag(Uppsala University), Benjamin Brenner(Rambam Health Care Campus), Amanda Brisco(University of South Florida), Nir Stanietzky(Baylor College of Medicine), Wasif M. Abidi(Baylor College of Medicine), Mohamed O. Othman(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), James Jing(Baylor College of Medicine), Bambj Grilley(Baylor College of Medicine), Jinyu Lu(Baylor College of Medicine), Kalpesh Patel(Baylor College of Medicine), Jessica Wenthe(Uppsala University), Emma Eriksson(Uppsala University), Eric K. Rowinsky(The University of Texas at San Antonio)
Cited by 12
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
|Blood|2003|442
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
|Science|2011|440
Preoperative Treatment of Locally Advanced Rectal Cancer
|New England Journal of Medicine|2023|440